Kyu-Uang Whang

Acquired reactive perforating collagenosis: Unilateral umbilicated papules along the lesions of herpes zoster

Reactive perforating collagenosis (RPC), originally described by Mehregan, Schwartz, and Livingood 1 in 1967, is an uncommon dermatosis characterized by transepidermal elimination of altered dermal collagen. A childhood or inherited form 2 and an adult or acquired form 3 have been recognized. Male and female persons are equally affected. 2, 4 The lesions are distributed mainly on trauma-prone areas such as the dorsum of the hands, forearms, elbows, and knees. 1 It can be associated with superficial trauma such as abrasions, scratches, and insect bites. 1 We describe a patient with diabetes mellitus and chronic renal failure in whom RPC developed during hemodialysis in an area previously involved with herpes zoster. To our knowledge this is the first report of this association.

A CASE OF DERMATOPATHIA PIGMENTOSA RETICULARIS

Dermatopathia pigmentosa reticularis (DPR) is a very rare disorder with the diagnostic triad of generalized reticulate hyperpigmentation, noncicatricial alopecia, and onychodystrophy. Many other dermatologic findings have been associated with this triad, including adermatoglyphia, hypohidrosis or hyperhidrosis, palmoplantar hyperkeratosis, and nonscarring blisters on the dorsa of the hands and feet. The mode of inheritance is unclear but may be autosomally dominant. To our knowledge, only 11 cases have been reported in the world, and none has previously been described in the Orient. We present a Korean patient with the typical features of the DPR triad, along with adermatoglyphia, hypohidrosis, and nonscarring blisters on the dorsa of the feet.

An unusual case of congenital dermal melanocytosis.

Dermal melanocytosis is characterized by the presence of ectopic melanocytes in the dermis. The most common forms include the Mongolian spot, blue nevus, nevus of Ota, and nevus of Ito. Some types of dermal melanocytosis do not fit into any of these morphologic categories, however. Our case demonstrated an extensive amount of uniform deep blue patches of nevi with unilateral distribution on the left face, neck, chest, shoulder, and back. On histopathologic examination, a number of elongated melanocytes scattered throughout the dermis were found. We herein report a case of congenital unilateral dermal melanocytosis.

The effect of proopiomelanocortin-derived peptides on the immune system of human hair follicles.

1 CACAGTGGCCTTATTGTCTC CAACCKGGATTGGATTGGAG 502 806 2 ATGCCTATAGTCCCAGGTAC GATGATGTTCGGCCTTGATG 254 297 3–4 CATGGTTTTGTTGTAGYTTGAG GTCRATATTGGGAGTCCTAGAA 455 532 5 ATCATTCAGCAGCCCATGTC AAGGGAAAATGTGGCTAGCA 515 186 6 AGCCATAGGTGTGAGCAGTT GCTYAGAAAAGGGAACCCTA 1241 496 7 GGGTTTCCTTCTAGTTATGG GGACTTACTGCCAAGATTTC 1149 1472 8 CTTCCTCAAGTAGCTAGAAC AGTGCTCATCAAACAGCTTG 1526 433 9 RATTTATGGCCTGCCTCTAG ACTTCTGGCYTCAAGCTCTC 296 206 10 GATCAGATACTGAGGTTGAAC GATGCAAATGCTCAAAACCTC 240 186

The duration of hyaluronidase and optimal timing of hyaluronic acid (HA) filler reinjection after hyaluronidase injection

ABSTRACT Background: Hyaluronidase injection is a commonly performed treatment for overcorrection or misplacement of hyaluronic acid (HA) filler. Many patients often wants the HA filler reinjection after the use of hyaluronidase, though the optimal timing of reinjection of HA filler still remains unknown. Objectives: To provide the optimal time interval between hyaluronidase injections and HA filler reinjections. Methods: 6 Sprague–Dawley rats were injected with single monophasic HA filler. 1 week after injection, the injected sites were treated with hyaluronidase. Then, HA fillers were reinjected sequentially with differing time intervals from 30 minutes to 14 days. 1 hour after the reinjection of the last HA filler, all injection sites were excised for histologic evaluation. Results: 3 hours after reinjection of HA filler, the appearance of filler material became evident again, retaining its shape and volume. 6 hours after reinjection, the filler materials restored almost its original volume and there were no significant differences from the positive control. Conclusions: Our data suggest that the hyaluronidase loses its effect in dermis and subcutaneous tissue within 3–6 hours after the injection and successful engraftment of reinjected HA filler can be accomplished 6 hours after the injection.